LB Pharmaceuticals has started its pivotal Phase III NOVA-2 trial to assess the safety and efficacy of its investigational ...
AstraZeneca’s IL-33 blocker, tozorakimab has significantly reduced the annualised rate of COPD exacerbations as an adjuvant to SoC inhaled therapy over placebo in two Phase III studies. Credit: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results